This study evaluated the clinical efficacy of Venoruton (O-(beta-hydroxyethyl)-rutosides) (HR) (Novartis Consumer Healthcare) in subjects with severe chronic venous insufficiency (CVI).
Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study / M.R. Cesarone, G. Belcaro, E. Ippolito, L. Pellegrini, A. Ledda, R. Luzzi, A. Ricci, M. Dugall, P. Bavera, M. Hosoi, S. Stuard, M. Corsi. - In: PANMINERVA MEDICA. - ISSN 0031-0808. - 52:2 Suppl 1(2010 Jun), pp. 43-48.
Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study
E. Ippolito;
2010
Abstract
This study evaluated the clinical efficacy of Venoruton (O-(beta-hydroxyethyl)-rutosides) (HR) (Novartis Consumer Healthcare) in subjects with severe chronic venous insufficiency (CVI).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
